alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Drug trials: efficacy and safety

902 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Discovery of Natural Cholinesterase Inhibitors via Integrated Computational Studies using Labdane-Related Diterpenoids-based Pharmacophore Model and in-vitro studies

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-06 Treatments

    Alzheimer’s disease (AD) represents a progressively growing worldwide public health burden.

  2. Cost-effectiveness of amyloid-targeting therapies in a memory clinic population; a simulation study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-08-02 Treatments

    The cost-effectiveness of ATTs is strongly influenced by the waning of the treatment effect.

  3. Computational Screening of FDA-Approved Drugs as Potential BACE1 Inhibitors for Alzheimer's Disease Drug Repurposing

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-27 Treatments

    Alzheimer's disease is a progressive neurodegenerative disorder affecting over 55 million people worldwide, with no disease-modifying treatments currently approved.

  4. Diphenhydramine Disrupts Sleep Architecture in 5XFAD Alzheimer’s Disease Model and Wild-Type Mice

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-07-27 Risk factors

    Sleep disruption is common in Alzheimer’s disease (AD).

  5. Comparator supplement patterns qualify the clinical interpretation of an EHR-derived glucosamine signal in Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-07-27 Prevention and risk

    Electronic health records linked documented glucosamine use to faster progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) and poorer survival after dementia.

  6. GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer’s Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-07-24 Drug development

    These findings reinforce the potential of GLP-1RAs and SGLT2i as therapeutic options to slow cognitive decline in DM2, possibly depending on glycemic control and central modulation.

  7. Effect of initiating an ARB- versus ACEI-based regimen on dementia risk, a target trial emulation of 2.5 million US Veterans

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-07-08 Drug development

    Among 2,577,000 Veterans (mean age, 63 years; 4.5% female; 65% White; 15% Black), 10% initiated ARBs and 90% initiated ACEIs.

  8. Protocol for the 2026 Nationwide Survey of Dementia Specialists on the Real-World Implementation of Anti-Amyloid Antibody Therapies in Japan: Clinical Practice, Blood Biomarkers, and Preference Experiments

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-07-01 End-of-life care

    Data collection started on June 3, 2026, and is planned to close on June 30, 2026.

  9. Amantadine, Donepezil and Memantine Associated Arrhythmia in an Elderly Patient

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-06-21 Treatments

    2.1 Case İnformation A 78 years old man was referred to the cardiology clinic because of mild dyspnea.

  10. Reducing placebo response in clinical trials of agitation in Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-06-04 Treatments

    High placebo response is an obstacle in developing drugs to treat agitation in Alzheimer’s disease (AAD), a prevalent and burdensome symptom.

  11. Assessment of potentially inappropriate medications using STOPPFrail V2 criteria and OncPal guideline in elderly cancer patients with end-stage disease: A cross-sectional study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-06-04 End-of-life care

    Polypharmacy and PIMs are highly prevalent in end-of-life elderly cancer patients.

  12. Sodium channel blockers are associated with reduced dementia risk in late-onset unexplained epilepsy

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-05-22 Down syndrome and Alzheimer's

    Late-onset unexplained epilepsy is a potential harbinger of dementia, likely driven by network hyperexcitability that facilitates amyloid-β release and tau propagation.

  13. Beyond Cardiology's Pillars: A Network Meta-Analysis Comparing the Recombinant Zoster Vaccine (Shingrix/RZV) with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Prevention of Major Adverse Cardiovascular Events and Dementia in Adults Aged ≥50 Years

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-05-19 Drug development

    Eligible studies reported MACE or dementia outcomes in adults ≥ 50 years for at least one of three intervention classes (RZV, SGLT2i, GLP-1 RA) versus placebo or active comparator, with follow-up ≥ 6 months.

  14. A Transferable Health Economic Evaluation Framework for Alzheimer’s Disease-Modifying Therapies

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-05-05 Costs and economics

    Base-case incremental cost-effectiveness ratios (ICERs) for lecanemab versus standard of care were €296,506 per QALY gained, and €371,299 per QALY for donanemab, from the HSE payer perspective under HIQA guidelines.

  15. Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lost

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-04-23 Drug development

    In propensity-matched comparator analyses, during the 2 year time-period from treatment initiation, semaglutide was associated with broadly lower neuropsychiatric event risk than metformin, SGLT2 inhibitors, and DPP-4 inhibitors.

  16. Treatment Effects of Cholinesterase Inhibitors in Alzheimer’s Disease: a Causal Machine Learning Approach

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-02-12 Treatments

    A bstract INTRODUCTION Treatment response in Alzheimer’s disease (AD) varies substantially across patients, yet no validated frameworks exist to estimate heterogeneous treatment effects (HTE) from observational data while controlling for confounding bias.

  17. Integrative Multimodal Subtyping, Risk of Incident Mild Cognitive Impairment, and Differential Cardiometabolic Treatment Effects: A Prospective Cohort Study in the All of Us Research Program

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-02-11 Drug development

    Four distinct subtypes were identified: I low-risk healthy aging, II behavioral/social vulnerability, III cardiometabolic–depressive multimorbidity, and IV mixed social-medical vulnerability profiles.

  18. Concurrent Gabapentin and Dihydropyridine Calcium Channel Blocker Use and Risk of Incident Dementia: An Active-Comparator Cohort Study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-02-09 Costs and economics

    Both classes act on neuronal calcium signaling, raising the question of whether their combined use is associated with greater cognitive risk than gabapentin alone.

  19. Pharmacotherapy for Alzheimer’s Disease and Dementias in Long-Term Care: A Real-World EHR Study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-01-19 Health systems and care delivery

    More than one-quarter of residents with ADRD remain untreated with guideline-recommended pharmacotherapy, and treatment varied significantly by non-clinical predictors.

  20. Lithium therapy and delayed progression of Alzheimer’s disease and related dementias in patients with bipolar disorder and mild neurocognitive disorders

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-01-13 Health systems and care delivery

    Recent mechanistic evidence identifies lithium deficiency as a driver of Alzheimer’s disease and related dementias (ADRD) pathogenesis.

  21. Budget Impact Analysis of Disease-Modifying Therapies for Alzheimer’s Disease in Ireland: A Model-Based Analysis

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-12-30 Treatments

    These therapies require complex diagnostic workup and safety monitoring, raising significant budget impact concerns for healthcare payers.

  22. Large Language Model-Driven Prioritization of Alzheimer’s Disease Drug Targets Across Multidimensional Criteria

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-12-29 Digital health tools

    Large language models (LLMs) offer new opportunities to synthesize the vast and heterogeneous biomedical literature, yet their potential to support drug target prioritization in complex diseases such as Alzheimer’s disease (AD) remains largely unexplored.

  23. The effects of vortioxetine versus placebo on cognitive functioning in mild cognitive impairment: a placebo-controlled, randomized, double-blind study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-12-11 Clinical trials

    In a recent open-label, single-arm study, vortioxetine, an antidepressant, was associated with improved cognitive function in patients with MCI, however, no placebo-controlled studies have been conducted to support these findings.

  24. Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-10-02 Treatments

    Our study examined the safety and tolerability of centralized lecanemab administration across a widely distributed region and suggests that use of distributed infusion sites increases access to disease-modifying treatment without significant increase in risk.

  25. XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-09-27 Treatments

    The complete absence of ARIA distinguishes XPro1595 from amyloid-targeting therapies and supports its potential for use in combination strategies and potentially for those at a higher risk of ARIA.

From across this topic

9 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

Other topics